| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001859453-26-000006.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001859453-26-000006.txt","company":"Vera Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001859453-26-000006.txt","article_chars":3113,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_b8a69cd5f14b3a9b","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001859453-26-000006.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:21:53.418742+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001859453-26-000006.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001859453-26-000006.txt","source_event_id":"evt_57a246a0dada","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"3386bfabd3230b37","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-15","2026-04-14","2026-01-09","2026-03-13"],"entities":[{"asset_class":"equity","name":"Vera Therapeutics, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"equity","name":"Fordyce Marshall","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"equity","name":"Class A Common Stock","relevance":"high","symbol":"","type":"security"},{"asset_class":"other","name":"2021 Employee Stock Purchase Plan","relevance":"medium","symbol":"","type":"plan"},{"asset_class":"other","name":"Rule 10b5-1(c)","relevance":"medium","symbol":"","type":"regulation"}],"event_type":"other","information_gaps":["The provided text does not clearly show the exact number of shares sold in each transaction/price range (only price ranges and some plan-acquired share count are visible).","The signal is labeled as a \u201cdelta,\u201d but no prior known state (what was previously disclosed) is included in the provided text, so the exact change vs prior state cannot be determined from this input alone."],"key_facts":["SEC accession number: 0001859453-26-000006; Form type: 4.","Issuer: Vera Therapeutics, Inc.; reporting person: Fordyce Marshall.","Conformed period of report: 2026-04-14; filed as of date: 2026-04-15.","The filing states the sale was made pursuant to a written plan adopted on January 9, 2026, meeting Rule 10b5-1(c) requirements.","The price reported is a weighted-average price; shares were sold in multiple transactions at prices ranging from $43.25 to $44.24 (inclusive).","The filing states the reporting person will provide full information regarding the number of shares sold at each separate price upon request.","The filing includes: \u201cIncludes 1,032 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2026.\u201d","Additional sale price ranges are stated as weighted-average prices with transactions at $44.25 to $45.20 (inclusive), and $45.25 to $45.67 (inclusive).","Signature: \u201c/s/ Joseph R. Young, Attorney-in-Fact\u201d dated 2026-04-15."],"numeric_claims":[{"label":"Form filing date (as of)","value":"2026-04-15"},{"label":"Conformed period of report","value":"2026-04-14"},{"label":"Plan adoption date (Rule 10b5-1(c))","value":"2026-01-09"},{"label":"Shares acquired under 2021 Employee Stock Purchase Plan","value":"1,032"},{"label":"Sale price range 1 (inclusive)","value":"$43.25 to $44.24"},{"label":"Sale price range 2 (inclusive)","value":"$44.25 to $45.20"},{"label":"Sale price range 3 (inclusive)","value":"$45.25 to $45.67"}],"primary_claim":"On April 15, 2026, Vera Therapeutics, Inc. filed Form 4 reporting that Fordyce Marshall sold shares of Vera\u2019s Class A Common Stock on April 14, 2026 at weighted-average prices across multiple transaction price ranges.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Vera Therapeutics, Inc. filed Form 4 on April 15, 2026 reporting insider activity by Fordyce Marshall. The filing indicates sales of Class A Common Stock on April 14, 2026 at weighted-average prices across multiple transaction price ranges, including shares acquired via the company\u2019s 2021 Employee Stock Purchase Plan.","topics":["SEC Form 4","insider trading","Class A Common Stock sales","10b5-1 plan","weighted-average sale price","Employee Stock Purchase Plan"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Vera Therapeutics, Inc. \u00b7 Filed 20260415","ticker":"VERA","tickers":["VERA"],"title":"VERA filed 4","url":"https://www.sec.gov/Archives/edgar/data/1831828/0001859453-26-000006.txt"}... |